Number of items: 8.
2023
Crabb, S. J. et al.
(2023)
A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma.
Journal of Clinical Oncology, 41(1),
pp. 54-64.
(doi: 10.1200/JCO.22.00405)
(PMID:35960902)
(PMCID:PMC9788980)
2022
Brown, Sarah R., Hinsley, Samantha
ORCID: https://orcid.org/0000-0001-6903-4688, Hall, Emma, Hurt, Chris, Baird, Richard D., Forster, Martin, Scarsbrook, Andrew F. and Adams, Richard A.
(2022)
A road map for designing phase I clinical trials of radiotherapy-novel agent combinations.
Clinical Cancer Research, 28(17),
pp. 3639-3651.
(doi: 10.1158/1078-0432.CCR-21-4087)
(PMID:35552622)
Homer, V. et al.
(2022)
Early phase clinical trials extension to guidelines for the content of statistical analysis plans.
British Medical Journal, 376,
e068177.
(doi: 10.1136/bmj-2021-068177)
(PMID:35131744)
(PMCID:PMC8819597)
2021
Tsim, S. et al.
(2021)
Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases.
Journal of Thoracic Oncology, 16(10),
pp. 1705-1717.
(doi: 10.1016/j.jtho.2021.05.018)
(PMID:34116230)
(PMCID:PMC8514249)
Spiliopoulou, Pavlina
ORCID: https://orcid.org/0000-0002-6486-6319, Hinsley, Samantha
ORCID: https://orcid.org/0000-0001-6903-4688, Mcneish, Iain A.
ORCID: https://orcid.org/0000-0002-9387-7586, Roxburgh, Patricia
ORCID: https://orcid.org/0000-0001-9869-591X and Glasspool, Rosalind
(2021)
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
International Journal of Gynecological Cancer, 31,
pp. 1037-1044.
(doi: 10.1136/ijgc-2021-002467)
(PMID:34016703)
2020
Hanna, C. R. et al.
(2020)
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Trials, 21(935),
(doi: 10.1186/s13063-020-04891-1)
(PMID:33213530)
(PMCID:PMC7675389)
Talhouk, A. et al.
(2020)
Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE).
Clinical Cancer Research, 26(20),
(doi: 10.1158/1078-0432.CCR-20-0103)
(PMID:32554541)
(PMCID:PMC7572656)
Millstein, J. et al.
(2020)
Prognostic gene expression signature for high-grade serous ovarian cancer.
Annals of Oncology, 31(9),
pp. 1240-1250.
(doi: 10.1016/j.annonc.2020.05.019)
(PMID:32473302)
(PMCID:PMC7484370)
This list was generated on Mon Sep 14 23:53:06 2026 BST.